ERBB2 and neoplasm: In an anti-tumour proliferative assay with HER2+ SKBR-3 cells, the divalent ADC showed 3-fold increase in IC50 compared to Kadcyla (IC50 50 pM), while the monovalent ADC demonstrated a similar IC50.